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Background and Aim: The relevance of dual antiplatelet therapy (DAPT) in acute ST-segment eleva-
tion myocardial infarction (STEMI) is well-established (aspirin and P2Y12 inhibitors).1 The role of gly-
coprotein (GP) IIb/IIIa inhibitors in clinical practice is not completely defined. Administration in the 
event of thrombotic complications is considered reasonable, although there is no evidence for routine 
use in primary percutaneous coronary intervention (pPCI). The aim was to analyze early outcomes of 
STEMI patients (pts) in the Croatian branch of the ISACS-CT (International Registry of Acute Coronary 
Syndromes in Transitional Countries) registry, depending on received antiaggregation therapy.
Patients and Methods: Data were gathered retrospectively from pts hospitalized between January 
2012 to October 2017. The study included 2503 pts with acute coronary syndrome, from which 48.9% 
(n=1224) were diagnosed with STEMI. The patients were divided into 4 groups depending on adminis-
tered antiaggregation therapy.
Results: For 7.8% (n=96) pts antiaggregation therapy data were missing, and 5.8% (n=71) were not treat-
ed with DAPT. Remaining 1057 (86.4%) pts were analyzed. Aspirin was administered in 95% of pts in 
the first 24 hours. 41.9% (n=443) of pts were additionally treated with clopidogrel, 16.1% (n=170) with tica-
grelor, 28.6% (n=302) with clopidogrel and eptifibatide, and 13.4% (n=142) with ticagrelor and eptifibatide 
(Table 1). The groups did not differ in comorbidities, while pts receiving eptifibatide had lower systolic 
blood pressure on admission. Patients treated with eptifibatide were more frequently male, smokers, 
of younger age, had more thrombotic complications seen on coronary angiography (predominantly 
distal embolisation and “no-reflow” phenomenon) and lower in-hospital mortality. In a multivariable 
regression model adjusted for age, gender, hypertension, diabetes, and pPCI, increasing age (OR=1.1), 
diabetes (OR=1.9) and pPCI (OR=0.5) remained relevant to in-hospital mortality.
Conclusion: STEMI patients that are young, male and smokers are more frequently treated with epti-
fibatide, likely due to a higher burden of thrombotic complications. Unlike the choice of antiaggrega-
tion therapy, increasing age, diabetes and non-invasive management of STEMI were associated with 
in-hospital mortality. 
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Male gender, n (%) 296 (66.8) 112 (65.9) 224 (74.2) 110 (77.5) 0.020
Age (IQR) 63 (53, 75) 66 (55, 77) 62 (54, 71) 59 (52, 68) 0.002
Hypertension, n (%) 294 (68.9) 119 (73.0) 199 (66.6) 91 (64.1) 0.348
Hypercholesterolemia, n (%) 179 (44.8) 68 (43.0) 150 (51.2) 76 (54.3) 0.085
Diabetes mellitus, n (%) 106 (24.3) 37 (22.3) 51 (16.9) 34 (23.9) 0.106
Chronic kidney disease, n (%) 32 (9.3) 10 (6.1) 23 (8.0) 7 (5.0) 0.344
Smoking, n (%) 221 (55.4) 87 (58.8) 179 (61.9) 96 (69.6) 0.025
HR median (IQR) 80 (70, 92) 80 (71, 94) 80 (70, 92) 78 (66, 92) 0.318
SBP median (IQR) 138 (120, 150) 135 (115, 153) 130 (112, 145) 130 (120, 150) 0.017
Creatinine (IQR) 95 (81, 112) 83 (72, 101) 93 (78, 111) 81 (69, 95) <0.001
hsTnT max median (IQR) 3.63 (1.45, 9.40) 3.2 (1.31, 7.74) 4.22 (1.90, 9.60) 4.86 (2.04, 8.93) 0.156
Platelets (IQR) 219 (188, 262) 229 (189, 265) 231 (187, 266) 231 (192, 258) 0.704
LVEF median (IQR) 50 (40, 55) 45 (40, 52) 45 (40, 55) 45 (40, 55) 0.007
pPCI, n (%) 338 (77.0) 152 (89.4) 294 (97.7) 139 (97.9) <0.001
Coronary angiography - number 
of lesions >2, n (%)
105 (31.1) 48 (30.4) 77 (25.8) 31 (22.1) 0.161
PCI - number of treated lesions 
>1, n (%)
57 (19.6) 38 (25.7) 55 (18.9) 26 (18.7) 0.350
Thrombotic complications, n 
(%)
29 (8.7) 9 (6.0) 48 (16.5) 29 (20.7) <0.001
Distal coronary embolisation 3 (0.9) 1 (0.7) 12 (4.1) 13 (9.3)
“No-reflow” phenomenon 10 (3.0) 3 (2.0) 11 (3.8) 5 (3.6)
Other 16 (4.8) 5 (3.3) 25 (8.6) 11(7.8)
In-hospital mortality, n (%) 33 (7.4) 14 (8.2) 9 (3.0) 5 (3.5) 0.020
ASA - acetylsalicylic acid; IQR - interquartile range; HR - heart rate; SBP - systolic blood pressure; hsTnT - high-sensitive troponin T; 
LVEF - left ventricular ejection fraction; pPCI - primary percutaneous coronary intervention; PCI - percutaneous coronary intervention.
TAbLe 1. patients’ characteristics.
